If we partner it is dilution too. We need cash.
The FDA is requesting further work on NSCLC.
" Chemotherapy-resistant lung cancer – ‘Tribetarna®’: Benitec’s lung cancer program targeting the gene responsible for chemotherapy resistance, beta III tubulin (TUBB3), continues to make encouraging progress toward the clinic. Significant milestones include:
o Continuing the development of Tribetarna® undertaking additional tox, biodistribution and efficacy studies requested by the FDA, and to optimise dosing and treatment regimes to enable maximal knockdown of the target gene, TUBB3, in the clinical setting
o Advancing the development of a Companion Diagnostic enabling identification of patients likely to benefit from treatment and correlation of efficacy with TUBB3 patient levels
o Professor Maria Kavallaris from UNSW published research identifying additional tumours that may benefit from treatment with Tribetarna®. These tumours include renal and pancreatic cancer."
Half yearly update would indicate 2016 IMO. Not IND ready yet and remember how much work the IND was.
- Forums
- ASX - By Stock
- BLT
- re: announcement of adr ipo
re: announcement of adr ipo, page-13
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BLT (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online